NASDAQ: RENBRenovaro Inc Stock
$0.36+0.02 (+5.88%)
Updated Apr 30, 2025
RENB Price
$0.36
Fair Value Price
-$0.04
Market Cap
$57.14M
52 Week Low
$0.30
52 Week High
$2.34
P/E
-0.4x
P/B
0.58x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$123.46M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.24
Operating Cash Flow
-$10M
Beta
1.13
Next Earnings
May 13, 2025
Ex-Dividend
N/A
Next Dividend
N/A
RENB Overview
Renovaro Biosciences Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer in the United States. The company's product pipeline includes RENB-HV-01 for autologous HIV curative treatment; RENB-HV-12, a therapeutic HIV vaccine; and RENB-HB-01, a gene therapy curative treatment for HBV. It also develops RENB-DC-11, an allogeneic dendritic cell therapeutic vaccine for pancreatic cancer; RENB-DC-12-XX, an allogeneic dendritic cell therapeutic vaccine for other solid tumors; and RENB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. It has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was formerly known as Enochian Biosciences, Inc. and changed its name to Renovaro Biosciences Inc. in August 2023. Renovaro Biosciences Inc. is headquartered in Los Angeles, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine RENB's potential to beat the market
- RENB doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
RENB
RankedUnranked of 462
RankedUnranked of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $3.07 | A | |
| $8.24 | A | |
| $24.29 | A |
Be the first to know about important RENB news, forecast changes, insider trades & much more!
RENB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how RENB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RENB ($0.36) is overvalued by 1,071.53% relative to our estimate of its Fair Value price of -$0.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
RENB ($0.36) is not significantly undervalued (1,071.53%) relative to our estimate of its Fair Value price of -$0.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
RENB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more RENB due diligence checks available for Premium users.
Valuation
RENB fair value
Fair Value of RENB stock based on Discounted Cash Flow (DCF)
Price
$0.36
Fair Value
-$0.04
Undervalued by
1,071.53%
RENB ($0.36) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
RENB ($0.36) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
RENB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
RENB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.4x
Industry
-162.28x
Market
29.18x
RENB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.58x
Industry
4.45x
RENB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RENB's financial health
Profit margin
Revenue
$0.0
Net Income
-$44.2M
Profit Margin
0%
RENB's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$121.8M
Liabilities
$23.7M
Debt to equity
0.24
RENB's short-term liabilities ($23.04M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RENB's short-term assets ($1.95M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RENB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
RENB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
$0.0
Financing
$2.0M
RENB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RENB vs Biotech Stocks
Renovaro Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.